Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890915407> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2890915407 endingPage "TPS8052" @default.
- W2890915407 startingPage "TPS8052" @default.
- W2890915407 abstract "TPS8052 Background: Multiple myeloma (MM) cells may evade immune surveillance by suppressing immune responses through the PD-1 pathway, via upregulation of PD-L1. 1 Nivolumab (nivo), a PD-1 immune checkpoint inhibitor that blocks PD-L1 interaction and disrupts MM-mediated PD-1 signaling, demonstrated modest activity as monotherapy in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in a phase 1b study. 2 Pomalidomide, an immunomodulatory drug (IMiD), may sensitize MM cells to PD-1 blockade, and has shown efficacy with dexamethasone (Pd) for RRMM. Elotuzumab (elo), an anti-SLAMF7 monoclonal antibody, directly activates natural killer cells and facilitates antibody-dependent cell-mediated cytotoxicity. Preclinical work suggests PD-1 blockade may enhance elo efficacy 3 ; thus nivo + Pd + elo may increase clinical benefit. Methods: CheckMate 602 (NCT02726581) is a phase 3, open-label, randomized study of efficacy and safety of nivo + Pd (N-Pd) vs Pd in pts with RRMM. Nivo combined with elo + Pd (NE-Pd) will be evaluated in an exploratory arm. Eligible pts must have measurable MM after ≥2 prior lines of therapy (LoTs) that included an IMiD and proteasome inhibitor, each for ≥2 consecutive cycles, alone or combined, and be refractory to their last LoT. Pts with prior elo are eligible. A planned 406 pts will be randomized 3:3:1 to N-Pd, Pd and NE-Pd, stratified by LoT (2 vs 3+) and International Staging System disease stage (I–II vs III). Pts in the Pd arm may cross over to the NE-Pd arm at disease progression. Pts are enrolled at 119 sites in 13 countries. Coprimary endpoints (N-Pd and Pd arms): objective response rate (ORR) and progression-free survival (PFS), assessed by an independent review committee. Secondary endpoints (N-Pd and Pd arms): time to response, duration of response, investigator-assessed ORR and PFS. Exploratory endpoints include ORR and PFS (NE-Pd arm), and safety/tolerability and minimal residual disease status (all arms). 1. Liu et al. Blood 2007;110:296–304 2. Lesokhin et al. JCO 2016;34:2698–704 3. Bezman et al. Haematologica 2016;101:161–2 [S450] Study support: BMS. Writing support: A Gill, Caudex, funded by BMS. Clinical trial information: NCT02726581." @default.
- W2890915407 created "2018-09-27" @default.
- W2890915407 creator A5020123690 @default.
- W2890915407 creator A5023276777 @default.
- W2890915407 creator A5029013179 @default.
- W2890915407 creator A5040710269 @default.
- W2890915407 creator A5043490010 @default.
- W2890915407 creator A5043526996 @default.
- W2890915407 date "2017-05-20" @default.
- W2890915407 modified "2023-10-18" @default.
- W2890915407 title "CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma." @default.
- W2890915407 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps8052" @default.
- W2890915407 hasPublicationYear "2017" @default.
- W2890915407 type Work @default.
- W2890915407 sameAs 2890915407 @default.
- W2890915407 citedByCount "7" @default.
- W2890915407 countsByYear W28909154072018 @default.
- W2890915407 countsByYear W28909154072020 @default.
- W2890915407 countsByYear W28909154072021 @default.
- W2890915407 countsByYear W28909154072022 @default.
- W2890915407 crossrefType "journal-article" @default.
- W2890915407 hasAuthorship W2890915407A5020123690 @default.
- W2890915407 hasAuthorship W2890915407A5023276777 @default.
- W2890915407 hasAuthorship W2890915407A5029013179 @default.
- W2890915407 hasAuthorship W2890915407A5040710269 @default.
- W2890915407 hasAuthorship W2890915407A5043490010 @default.
- W2890915407 hasAuthorship W2890915407A5043526996 @default.
- W2890915407 hasConcept C121332964 @default.
- W2890915407 hasConcept C121608353 @default.
- W2890915407 hasConcept C126322002 @default.
- W2890915407 hasConcept C142424586 @default.
- W2890915407 hasConcept C143998085 @default.
- W2890915407 hasConcept C2776063141 @default.
- W2890915407 hasConcept C2776364478 @default.
- W2890915407 hasConcept C2776694085 @default.
- W2890915407 hasConcept C2777701055 @default.
- W2890915407 hasConcept C2778524551 @default.
- W2890915407 hasConcept C2778822529 @default.
- W2890915407 hasConcept C2780030458 @default.
- W2890915407 hasConcept C2780057760 @default.
- W2890915407 hasConcept C2780401358 @default.
- W2890915407 hasConcept C71924100 @default.
- W2890915407 hasConcept C87355193 @default.
- W2890915407 hasConceptScore W2890915407C121332964 @default.
- W2890915407 hasConceptScore W2890915407C121608353 @default.
- W2890915407 hasConceptScore W2890915407C126322002 @default.
- W2890915407 hasConceptScore W2890915407C142424586 @default.
- W2890915407 hasConceptScore W2890915407C143998085 @default.
- W2890915407 hasConceptScore W2890915407C2776063141 @default.
- W2890915407 hasConceptScore W2890915407C2776364478 @default.
- W2890915407 hasConceptScore W2890915407C2776694085 @default.
- W2890915407 hasConceptScore W2890915407C2777701055 @default.
- W2890915407 hasConceptScore W2890915407C2778524551 @default.
- W2890915407 hasConceptScore W2890915407C2778822529 @default.
- W2890915407 hasConceptScore W2890915407C2780030458 @default.
- W2890915407 hasConceptScore W2890915407C2780057760 @default.
- W2890915407 hasConceptScore W2890915407C2780401358 @default.
- W2890915407 hasConceptScore W2890915407C71924100 @default.
- W2890915407 hasConceptScore W2890915407C87355193 @default.
- W2890915407 hasIssue "15_suppl" @default.
- W2890915407 hasLocation W28909154071 @default.
- W2890915407 hasOpenAccess W2890915407 @default.
- W2890915407 hasPrimaryLocation W28909154071 @default.
- W2890915407 hasRelatedWork W2123159083 @default.
- W2890915407 hasRelatedWork W2200095709 @default.
- W2890915407 hasRelatedWork W2582819487 @default.
- W2890915407 hasRelatedWork W2590875813 @default.
- W2890915407 hasRelatedWork W2765526403 @default.
- W2890915407 hasRelatedWork W2889508208 @default.
- W2890915407 hasRelatedWork W2900068404 @default.
- W2890915407 hasRelatedWork W2980591007 @default.
- W2890915407 hasRelatedWork W3007230085 @default.
- W2890915407 hasRelatedWork W3195616002 @default.
- W2890915407 hasVolume "35" @default.
- W2890915407 isParatext "false" @default.
- W2890915407 isRetracted "false" @default.
- W2890915407 magId "2890915407" @default.
- W2890915407 workType "article" @default.